55 results about "Specific protein" patented technology

The application discloses a Campylobacter-specific protein antibody, an antibody-coupled magnetic bead and application. The antibody is a monoclonal antibody 1A10 and a monoclonal antibody 3D9, the monoclonal antibody 1A10 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 1A10 are shown in SEQ ID NO: 7 and 8 respectively; the monoclonal antibody 3D9 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 3D9 are shown in SEQ ID NO: 9 and 10 respectively. The antibody-coupled magnetic bead is coupled by the monoclonal antibody 1A10, the monoclonal antibody 3D9 and activated carboxyl magnetic beads respectively. The antibody-coupled magnetic bead can specifically enrich Campylobacter, has high enrichment efficiency, simple enrichment operation, can be applied to metabolic product analysis of Campylobacter, and can be used for qualitative and quantitative analysis of the Campylobacter.

This invention discloses an antibody targeting a specific protein of *Lactobacillus* and its applications. The monoclonal antibody of this invention is any one of monoclonal antibody 1B3, monoclonal antibody 3B5, monoclonal antibody 2E5, and monoclonal antibody 3D8, which respectively recognize proteins Srt A, Cps C, ENO 1, and Fts Z. The magnetic bead antibody conjugate is prepared by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich *Lactobacillus* bacteria with high enrichment efficiency and simple operation. It can be applied to the identification of metabolites of *Lactobacillus* bacteria, as well as their qualitative and quantitative analysis.

The application provides a kind of liposome that can enhance organ targeting, preparation method and application, belongs to the field of biological medicine and nanotechnology.The application first proposes the strategy of actively regulating LNP organ targeting by pre-assembling specific protein crown in vitro, which breaks through the technical limitations of traditional passive formation of natural protein crown.Through selecting main lipids (CDO, CDA, EDM) with different head chemical structures, precise control of protein crown composition is realized.Furthermore, the method of the application is simple in process and mild in condition, only needs standard in vitro incubation steps, and has great clinical transformation potential.The pre-assembled protein crown method provided by the application significantly enhances the organ targeting efficiency of LNP: after pre-incubation of LNP1 with APOA1, the enrichment degree of spleen is increased by 2.8 times;after pre-incubation of LNP2 with VTN, the enrichment degree of lung is increased by 52%;after pre-incubation of LNP3 with APOE, the enrichment degree of liver is increased by 1.2 times.

This invention discloses an antibody against a specific protein of *E. rectum*, a magnetic bead antibody-conjugate, and their applications. The monoclonal antibody is either monoclonal antibody 4D3F6H7 or monoclonal antibody 5C8E7D6. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 4D3F6H7 are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 5C8E7D6 are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The magnetic bead antibody-conjugate is obtained by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody-conjugate of this invention can specifically enrich *E. rectum* with high enrichment efficiency and simple operation. It can be applied to the identification of *E. rectum* metabolites, as well as their qualitative and quantitative analysis.

This invention belongs to the field of biotechnology and discloses a nucleic acid aptamer that specifically recognizes placental-specific protein 1 and its uses. The nucleotide sequence of the nucleic acid aptamer includes any one of the sequences shown in SEQ ID No. 1-57. This invention employs X-aptamer screening technology, combined with high-throughput sequencing technology and bioinformatics analysis, to reduce the number of screening rounds and obtain candidate nucleic acid aptamers. Further analysis of their affinity and specificity yields a nucleic acid aptamer that specifically recognizes placental-specific protein 1. The nucleic acid aptamer of this invention has the characteristics of high affinity and specificity, good stability, convenient synthesis, and easy labeling of functional groups. It can be used for the detection or binding of placental-specific protein 1, the diagnosis of placental-specific protein 1-related diseases, and the preparation of products for prognosis.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

This application belongs to the field of biotechnology, specifically relating to giant salamander skin collagen peptides, their preparation methods, and applications. This application provides a method for preparing giant salamander skin collagen peptides. The method first pre-treats the fish skin, then performs ultrasonic-assisted extraction under acidic conditions to effectively promote collagen dissolution. The extract undergoes flocculation to remove impurities, significantly reducing interference from other proteins. The enzymatic hydrolysis stage employs a stepwise enzymatic hydrolysis strategy: first, a combination of alkaline protease and another specific protease is used for hydrolysis, sequentially cleaving the complex structure of giant salamander skin collagen to improve initial hydrolysis efficiency and generate specific intermediate peptides; subsequently, a flavor protease is added for further deep hydrolysis to achieve complete hydrolysis. This method has high enzymatic hydrolysis efficiency, controllable hydrolysis degree, concentrated molecular weight distribution of the obtained collagen peptides, high yield of the target product, and stable process.

This invention relates to the field of sample detection technology, and particularly to an integrated sample processing and detection system and method. The system includes a base, which includes a mounting platform and a support frame mounted thereon. A moving track is provided on the support frame, and the moving track forms a module installation line in the projection area on the mounting platform. The module installation line has several sample placement slots for placing reaction cups. The detection module includes at least two detection mechanisms located on the module installation line, which are biochemical analysis detection mechanisms, specific protein analysis detection mechanisms, or chemiluminescence analysis detection mechanisms. The sampling module includes a main moving component and a main sampling needle mounted thereon. The main moving component is slidably connected to the moving track to drive the main sampling needle to move along the module installation line between the sample placement slots and the detection mechanisms. This configuration simplifies the sample processing and detection process, reduces costs, and saves space.

The application discloses a Bifidobacterium lactis specific protein antibody, an antibody conjugated magnetic bead and application. The antibody is a monoclonal antibody BL1, comprising a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NO: 3 and 4 respectively. The antibody conjugated magnetic bead is coupled by the monoclonal antibody BL1 and activated carboxyl magnetic beads. The antibody conjugated magnetic bead can specifically enrich Bifidobacterium lactis, has high enrichment efficiency, simple enrichment operation, and can be applied to identification of metabolic products of Bifidobacterium lactis, and can be used for qualitative and quantitative analysis.

This invention discloses an antibody against a Bacteroides monoclonal protein, a magnetic bead antibody conjugate, and their applications. The monoclonal antibody is either monoclonal antibody 2F8 or monoclonal antibody 3C10. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 2F8 are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively, and the amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 3C10 are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The magnetic bead antibody conjugate is obtained by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich Bacteroides monoclonal with high enrichment efficiency and simple enrichment operation. It can be applied to the identification of Bacteroides monoclonal metabolites, as well as their qualitative and quantitative analysis.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

The application discloses a method for inducing Breg cell proliferation in vitro. The method comprises the following steps: (1) culturing B cells derived from mammals in a culture medium containing CD40 antibodies; (2) adding SARS-CoV-2 virus antigens to the culture system, wherein the SARS-CoV-2 virus antigens are selected from one or more of N protein, S protein specific epitope peptide segments or S1 subunits containing RBD regions of S protein; and (3) after 24-96 hours of culture, the induction of Breg cells is achieved. The application uses SARS-CoV-2 specific protein antigens to significantly improve the proportion of B cell conversion to Breg cells, and realizes the specific induction of Breg (CD19 + IL-10 + ) cell proliferation and differentiation under in vitro conditions.

The present invention describes an automated device for immunohistochemical staining, which includes an antibody dispenser for the localization of specific proteins in histological samples. It also has a receptacle with integrated connectors for radial sample distribution to minimize handling and thus prevent alterations in the results. The automated device for immunohistochemical staining incorporates a container with dividers that allows for the placement of different types of reagents for applying dyes to the samples. The present invention includes a control panel with a control module to fully automate sample processing, and the necessary adjustments for starting the process are made via a screen.

The application discloses an antibody of a specific protein of a bacterium of the genus Ruminococcus and application thereof. The monoclonal antibody of the application is any one of monoclonal antibody 3F, monoclonal antibody 6D, monoclonal antibody 10E and monoclonal antibody 2C, and the monoclonal antibody 3F, the monoclonal antibody 6D, the monoclonal antibody 10E and the monoclonal antibody 2C recognize proteins glgA, glgB, GH18 and pulA respectively. The magnetic bead antibody conjugate is obtained by coupling the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of the application can specifically enrich the bacterium of the genus Ruminococcus, has high enrichment efficiency, is simple in enrichment operation and can be applied to identification of metabolic products of the bacterium of the genus Ruminococcus and also can be used for qualitative and quantitative analysis.

This invention belongs to the field of molecular diagnostics, specifically relating to a biomarker combination, composition, and kit for assisting in the prediction of pancreatic cancer metastasis. The invention provides a biomarker combination for assisting in the prediction of pancreatic cancer metastasis, comprising: the extracellular domain of free receptor tyrosine kinase (sAXL) and growth arrest-specific protein 6 (GAS6). Using the biomarker combination of this invention, the extracellular domain of free plasma membrane proteins in a sample can be accurately identified, thereby providing a reference for the activation status of signaling pathways and the identification of potential targets and biomarkers for disease treatment and / or prevention.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.

The application discloses discovery and application of desmin autoantibody as a marker of nervous system diseases. The application finds that only the fluorescent signal existing in the nervous system disease patients but not in the healthy people, and the fluorescent mode of the IgG related autoimmune antibody in the mouse brain tissue section is different, which indicates that the patient may have autoimmune antibody. Through the immunoprecipitation technology, the IgG specific protein related to the nervous system disease is sought, the specific desmin autoantibody is found by adopting the CBA mode, and then the desmin autoantibody is verified in the cerebrospinal fluid, so that it is finally determined that the desmin autoantibody can be used as a specific marker for diagnosing the nervous system autoimmune diseases. The expression of the desmin autoantibody is detected by taking the desmin as a detection antigen, and the detection of the desmin autoantibody can be applied to a kit for detecting the desmin autoantibody, and can be applied to the detection of the nervous system diseases, so that the marker for identifying the nervous system diseases is enriched, and the accuracy of the detection of the nervous system related diseases is improved.

The present invention addresses the problem of providing: a method for simply and accurately detecting a specific protein contained in extracellular vesicles; and a membrane permeabilization treatment agent that can be used in the method. A method for detecting a specific protein contained in extracellular vesicles, the method comprising (A) a step for capturing extracellular vesicles using a carrier capable of binding to an extracellular vesicle-specific marker which exists on the surface of extracellular vesicles, (B) a step for performing a membrane permeabilization treatment on extracellular vesicles captured by the carrier using a membrane permeabilization treatment agent, and (C) a step for introducing a reagent capable of detecting a specific protein contained in extracellular vesicles, into the extracellular vesicles subjected to the membrane permeabilization treatment, wherein the step (B) is carried out such that the specific protein is prevented from leaking off the extracellular vesicles, and the reagent can be introduced into the extracellular vesicles.

The present application belongs to the technical field of skin care products, and particularly relates to a PDRN anti-aging composition, a preparation method thereof and application. The present application uses hydrolyzed sponges to open the absorption channels of the stratum corneum, and uses the specific proteins, polypeptides in hydrolyzed royal jelly protein and wheat glutelin and PDRN to form a stable molecular structure through van der Waals force, so as to enhance the stability of PDRN and promote the activity of PDRN. The high-energy phosphate bond of sodium mannose phosphate can enhance the activity of mitochondria, provide more energy for the penetration and absorption of PDRN and the exertion of efficacy, and tetrahydro methyl pyrimidine carboxylic acid is used to relieve the irritation of hydrolyzed sponges. Therefore, the PDRN anti-aging composition provided by the present application has a synergistic effect between the components. The data of the examples show that the PDRN anti-aging composition provided by the present application has good penetration and anti-aging effect.

New peptides (cPEPs) having a size from 4 to 70 amino acid residues and a method for preparing the cPEPs. Also, a method for modulating the accumulation of specific proteins in plant cells by introducing the cPEPs into the plant cells. The cPEPs may be introduced to either promote the development of a plant or slow down or prevent the development of a plant.

The application discloses a kind of zürich true bacillus genus specific protein monoclonal antibody TC1 and its application.The monoclonal antibody TC1 includes heavy chain variable region and light chain variable region, and the amino acid sequences of heavy chain variable region and light chain variable region are respectively shown as SEQ ID NO:3 and 4.The antibody conjugated magnetic bead of the application is coupled from the monoclonal antibody TC1 and activated carboxyl magnetic bead.The antibody conjugated magnetic bead of the application can specifically enrich zürich true bacillus genus, and the enrichment efficiency is high, and the enrichment operation is simple, can be applied to the analysis of zürich true bacillus genus metabolite, and can be used for its qualitative and quantitative analysis.

The utility model discloses a small specific protein analysis appearance, including instrument frame, the reagent detection module, sample adding arm group module, stirring arm group module, pH value and specific gravity detection module are arranged in the instrument frame, the reagent detection module includes the fixed installation of fixed installation's bath disc from outside to inside coaxial arrangement on the base, the sample detection turntable of rotary installation, the fixed installation's reagent refrigerator and the reagent turntable of rotary installation, a plurality of reagent sites have on the reagent turntable, a plurality of sample sites and a plurality of reaction cup sites have on the sample detection turntable, the bath disc has optical detection module group, the sample adding arm group module includes sample adding needle, the sample adding needle has two movement degrees of freedom of Y direction and Z direction, the stirring arm group module includes stirring needle, and the stirring needle has two movement degrees of freedom of Y direction and Z direction.

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

The application discloses a kind of shigella bacteria specific protein antibodies and its application.The antibody is monoclonal antibody C65 and monoclonal antibody A61, monoclonal antibody C65 includes light chain variable region and heavy chain variable region, and the amino acid sequences of light chain variable region and heavy chain variable region are respectively shown as SEQ ID NO:7 and 8;Monoclonal antibody A61 includes light chain variable region and heavy chain variable region, and the amino acid sequences of light chain variable region and heavy chain variable region are respectively shown as SEQ ID NO:9 and 10.The magnetic bead antibody conjugate of the application is coupled by monoclonal antibody C65, monoclonal antibody A61 and activated carboxyl magnetic bead respectively.The magnetic bead antibody conjugate of the application is specific to shigella bacteria, and enrichment efficiency is high, and enrichment operation is simple, can be applied to shigella bacteria metabolite analysis, and also can be used for its qualitative and quantitative analysis.

The application discloses a novel coronavirus vaccine for promoting specific IgA antibody secretion and a construction method and application thereof, belongs to the field of immunology and the field of genetic engineering, and is an immunogen developed by taking S protein as the vaccine (the same is true for other structural proteins of the novel coronavirus, such as N protein or E protein or M protein), aims to improve the mucosal IgA expression level after immunization of the vaccine, and constructs a novel coronavirus vaccine which can significantly promote human B lymphocytes to secrete specific anti-S protein IgA antibodies in the process of stimulating the immune response of the body by the S protein, and further enhance the mucosal protection and defense function, and provides a construction technology, method and application thereof. By introducing a specific protein domain, IL-5 (referred to as 'adjuvant protein'), into the S protein of the novel coronavirus, a novel coronavirus vaccine modified by the 'adjuvant protein' is formed.

Novel non-naturally occurring peptides that are not naturally produced by a plant (cPEPs) and novel naturally occurring peptides that are naturally produced by the plant (altPEPs). Also, the method for preparing the cPEPS and altPEPs and the use of the cPEPS and altPEPs for modulating the accumulation of specific proteins in the plant.

A technique for detecting a specific protein that is suitable as a cancer marker with high sensitivity. This technique includes a method for detecting CEACAM1, which involves denaturing CEACAM1 in a CEACAM1-containing specimen to produce a denatured CEACAM1; and detecting CEACAM1 by a sandwich assay using both a capture antibody and a labeled antibody that have an ability to recognize the denatured CEACAM1.

The application discloses a gradient crosslinking preparation method of a high-selectivity blood low-density lipoprotein adsorption resin, and the adsorption resin is in a granular form, has a gradient crosslinking structure with gradually reduced crosslinking degrees from the outside to the inside in the radial direction, and forms a multistage pore structure of a large hole-mesopore-micropore inside; a lipoprotein recognition ligand is fixed on the resin particles, and an anti-protein contamination layer is arranged on the outer surface; during preparation, porous polymer microspheres are prepared through suspension polymerization, the diffusion process of a crosslinking agent from the outside to the inside is controlled to form the gradient crosslinking, then functional groups are introduced, the ligand is fixed, and surface modification is performed. Through the partition design of the outer anti-contamination layer, the middle layer recognition and the inner layer mass transfer, and the synergistic effect of the gradient crosslinking and the multistage pore structure, the selective adsorption capacity of the resin for low-density lipoprotein is significantly improved, non-specific protein adsorption is reduced, and the resin has good blood compatibility and regeneration stability.